Highlights Newsletter 3
This newsletter presents you the following key sessions:
4. Daratumumab-VCd superior to VCd alone in newly diagnosed light chain amyloidosis
This newsletter presents you the following key sessions:
4. Daratumumab-VCd superior to VCd alone in newly diagnosed light chain amyloidosis
Medical writer
Medical writer